Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler ...

Fintel reports that on March 12, 2025, Piper Sandler upgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Neutral ...

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its ...

Myriad Genetics (MYGN) stock was upgraded to Overweight by Piper Sandler, citing a balanced risk-reward set up for its beaten ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Myriad Genetics is down 21.1% since the beginning of the year, and at $10.65 per share, it is trading 62.8% below its 52-week high of $28.60 from September 2024.

Piper Sandler upgraded Myriad Genetics (MYGN) to Overweight from Neutral with a price target of $12.50, up from $11.50. The stock is down more ...

Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...

Fintel reports that on March 12, 2025, Piper Sandler upgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Neutral to Overweight. As of March 4, 2025, the average one-year price target ...

UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad ...

On Wednesday, Piper Sandler analyst Dave Westenberg upgraded Myriad Genetics (NASDAQ:MYGN) stock from Neutral to Overweight, setting a new price target of $12.50, up from the previous target of ...